Talis Appoints Jeryl Hilleman to Board of Directors
March 18 2021 - 7:00AM
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to
developing innovative molecular diagnostic tests for infectious
diseases at the point-of-care, today announced the appointment of
Jeryl “Jeri” Hilleman to its Board of Directors. Ms. Hilleman will
serve as Chair of the Audit Committee.
“We welcome Jeri to our Board and look forward to
benefitting from her public company leadership as a chief financial
officer and corporate director at multiple life science companies,”
said Brian Coe, Chief Executive Officer of Talis. “Jeri’s
experience and guidance will be instrumental as we continue to
scale our business in preparation for the commercial launch of
Talis One™.”
Ms. Hilleman brings over 20 years of executive
leadership and financial experience to Talis. She currently serves
as Chairman of the Board of Omada Health and is a Director of
Novocure, SI-Bone and Minerva Neurosciences. Prior to her decision
to focus on board responsibilities full time in 2020, Ms. Hilleman
served as a Chief Financial Officer for more than 20 years at
multiple public companies in the life science industry, including
Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and
Cytel.
“Driven by the opportunity to help companies define
growth strategies, I look forward to working with the Talis Board
and leadership team in their efforts to transform diagnostic
testing for infectious diseases at the point-of-care,” said Ms.
Hilleman.
Ms. Hilleman graduated from Brown University and
earned an MBA from the Wharton School of the University of
Pennsylvania. She is a member of the 1999 class of Henry Crown
Fellows and the Aspen Global Leadership Network at the Aspen
Institute.
About the Talis One PlatformThe
Talis One platform is a compact, sample-to-answer, cloud-enabled,
molecular diagnostic solution that, once authorized for marketing,
could be rapidly deployed to distributed diagnostic settings in the
United States and around the world to diagnose infectious diseases
at the point-of-care. The Talis One assays are based on a highly
optimized nucleic acid isothermal amplification chemistry to
achieve test performance faster than traditional polymerase chain
reaction (PCR) tests. The Talis One platform is designed for use in
non-laboratory settings, such as physicians’ offices, hospital
emergency departments, urgent care clinics, ambulatory surgery
centers, elder care/assisted living facilities, and cancer
treatment and dialysis centers.
COVID-19 is the first infectious disease that the
Talis One platform is designed to detect. Future infectious disease
indications may include assays for other respiratory infections,
such as influenza, as well as sexually transmitted infections
(STIs) and other infections impacting women’s health. The Talis One
platform, currently in development, is designed to be managed
remotely, to send test results to a cloud database for secure
transmission, storage and review, and to return results in
approximately 25 minutes.
About TalisTalis is dedicated to
transforming diagnostic testing by developing and commercializing
innovative products that are designed to enable accurate, low cost
and rapid molecular testing for infectious diseases at the
point-of-care, beginning with COVID-19. The company is developing
Talis One, a compact, sample-to-answer, cloud-enabled, molecular
diagnostic platform. Talis is headquartered in Menlo Park,
California. For more information, please visit talis.bio.
Contact:Media & InvestorsEmily
Faucetteefaucette@talisbio.com+1.415.595.9407
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Apr 2024 to May 2024
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From May 2023 to May 2024